title: Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
abstract: We report a 62-year-old female liver transplant patient who presented with sirolimus (SIR)-related pneumonitis (SIP) treated with a switch to everolimus (EVER). At 13-month follow-up, the patient is on EVER monotherapy with no recurrence of SIP. Despite common mechanisms of action, the safety profile of EVER is different from SIR, and a switch from SIR to EVER should be contemplated in cases of SIP to allow patients to benefit from the antifibrotic properties of antiproliferative immunosuppressants.
authors: Liver Transplant Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
authors: P
authors: P
authors: De Simone
authors: S
authors: S
authors: Petruccelli
authors: A
authors: A
authors: Precisi
authors: P
authors: P
authors: Carrai
authors: R
authors: R
authors: Doria
authors: F
authors: F
authors: Menichetti
authors: F
authors: F
authors: Filipponi
mesh_terms: D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced*; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus